The IPO of Anthem Biosciences was fully subscribed by the second day of bidding, receiving bids for 5.08 crore shares against 4.4 crore on offer. Non-institutional investors led the demand with 2.82x subscription. Retail and QIB participation stood at 89% and 38%, respectively. Grey market premium of Rs 110–119 indicates a potential 19% upside.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets